ACHENMUEHLE, Duitsland–(BUSINESS WIRE)– Ziekten van de alvleesklier kunnen ernstige gevolgen hebben voor patiënten en zijn moeilijk te diagnosticeren. Vroege opsporing is cruciaal voor de overlevingskans van de patiënt. In Europa sterft meer dan 90 procent van de patiënten binnen de eerste vijf jaar na de diagnose aan alvleesklierkanker. De Medi-Globe Group, een toonaangevend internationaal MedTech-bedrijf gevestigd in Achenmühle, Beieren, zal, in samenwerking met het Franse Institut Hospitalo-Universitaire (IHU) Straatsburg, ‘s werelds eerste AI-software ontwikkelen voor de detectie van ziekten van de pancreas in endoscopische echografie (EUS) examen. De belangrijkste technologie hier is kunstmatige intelligentie. Als onderdeel van grootschalige klinische onderzoeken voorafgaand aan marktintroductie, is de AI-software nu in klinische test gegaan met patiënten, zogenaamde first-in-human toepassingen.

Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/20220516005559/en/

Innovative AI software for the detection of pancreatic diseases: first-in-human application successful

ACHENMUEHLE, Germany–(BUSINESS WIRE)– Diseases of the pancreas can have serious consequences for patients and are difficult to diagnose. Early detection is crucial for the patient’s chance of survival. In Europe today, more than 90 percent of patients die of pancreatic cancer within the first five years after diagnosis. The Medi-Globe Group, a leading international MedTech company based in Achenmühle, Bavaria, will, in cooperation with the French Institut Hospitalo-Universitaire (IHU) Strasbourg, develop the world’s first AI software for the detection of diseases of the pancreas in endoscopic ultrasound (EUS) examination. The key technology here is artificial intelligence. As part of large-scale clinical studies prior to market introduction, the AI ​​software has now gone into clinical test with patients, so-called first-in-human applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005559/en/

The new AI software has the potential to revolutionize the diagnosis of pancreatic diseases. Photo: Medi-Globe Group

“The new software has the potential to revolutionize the diagnosis of pancreatic diseases and, above all, the diagnosis of pancreatic cancer. That would be a dream for society as a whole and an important milestone in medicine and for medical technology,” says Prof. Dr. Leonardo Sosa Valencia, one of the leading gastroenterologists in the world and a top expert in the field of pancreatic disease detection.

The AI ​​software brings together the clinical experience of the world’s most experienced gastroenterologists. It bundles the knowledge from countless EUS examinations of the pancreas in an algorithm and transforms it into use in endoscopic ultrasound. The expert knowledge is used to train a neural network according to the deep learning method. For the diagnosis, it is crucial to recognize pathologically altered areas in the pancreas at an early stage so that a fine needle biopsy can accurately take tissue samples for further analyses and as basis for therapy decisions.

“With the AI ​​software, in the future we will be able to provide gastroenterologists with a virtual expert and give them the opportunity to significantly improve the diagnostics that determine therapy. Very good results have already been achieved in the first clinical applications. Small lesions were detected, even in complex cases. This gives the treating physicians and, above all, the patients great hope for improvement of patient care in the medium term,” says Dr. Markus Schönberger, Director of Business Development at the Medi-Globe Group.

Learn more about Medi-Globe Group at: https://medi-globe-group.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005559/en/

Contacts

braun communications

Stefanie Braun

+49 171 2 888 214

sb@brauncommunications.de
press@medi-globe.de